Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scient...
TD Cowen analyst Stacy Ku reinstates BioCryst Pharma (NASDAQ:BCRX) with a Buy and announces $30 price target.
Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overweight and raises the price ta...
JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the pri...
Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the price target from $17 to $20.
BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit...
